Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 4/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29359806 | 1.00 | AR (1.00) | AR | |
| SCHEMBL16871452 | 1.00 | AR (1.00) | AR | |
| SCHEMBL2450766 | 1.00 | AR (1.00) | AR | |
| SCHEMBL14522362 | 0.92 | AR (0.85) | AR | |
| SCHEMBL607245 | 0.91 | AR (0.84) | AR | |
| SCHEMBL607246 | 0.91 | AR (0.84) | AR | |
| SCHEMBL3698441 | 0.91 | AR (1.00) | AR | |
| SCHEMBL2746561 | 0.91 | AR (1.00) | AR | |
| SCHEMBL14252926 | 0.91 | AR (0.85) | AR | |
| SCHEMBL12706742 | 0.91 | AR (0.85) | AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 118 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2276496-B1 | THERAPEUTIC MODULATION OF OCULAR SURFACE LUBRICATION | UNIV CALIFORNIA (US) | 2019-07-10 | — | — | EP | claimed |
| US-9421241-B2 | Therapeutic modulation of ocular surface lubrication | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-08-23 | — | — | US | claimed |
| US-20160015780-A1 | Therapeutic Modulation of Ocular Surface Lubrication | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2016-01-21 | — | — | US | claimed |
| US-9138457-B2 | Therapeutic modulation of ocular surface lubrication | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2015-09-22 | — | — | US | claimed |
| WO-2009137602-A1 | THERAPEUTIC MODULATION OF OCULAR SURFACE LUBRICATION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2009-11-12 | — | — | WO | claimed |
| US-20230172897-A1 | METHODS OF TREATING BREAST CANCERS WITH SELECTIVE ANDROGEN RECEPTOR MODULATORS AND ADDITIONAL THERAPEUTIC AGENTS | VERU, INC. (US) | 2023-06-08 | — | — | US | disclosed |
| US-20210254056-A1 | IDENTIFICATION AND TARGETED MODULATION OF GENE SIGNALING NETWORKS | CAMP4 THERAPEUTICS CORPORATION | 2021-08-19 | — | — | US | disclosed |
| US-20210228529-A1 | PHARMACEUTICAL COMPOSITIONS FOR TREATING BREAST CANCERS AND METHODS OF USES THEREOF | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2021-07-29 | — | — | US | disclosed |
| US-20210128513-A1 | NON-INVASIVE METHOD OF EVALUATING BREAST CANCERS FOR SELECTIVE ANDROGEN RECEPTOR MODULATOR (SARM) THERAPY | UN IVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2021-05-06 | — | — | US | disclosed |
| US-10987334-B2 | Method of treating ER mutant expressing breast cancers with selective androgen receptor modulators (SARMs) | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2021-04-27 | — | — | US | disclosed |
| US-10849873-B2 | Non-invasive method of evaluating breast cancers for selective androgen receptor modulator (SARM) therapy | ONCTERNAL THERAPEUTICS, INC (US) | 2020-12-01 | — | — | US | disclosed |
| WO-2020160452-A1 | COMBINING SERMS, SARMS, AND CANNABINOIDS FOR IMPROVING SAFETY AND EFFICACY OF ENDOCRINE THERAPIES | TESS VENTURES, INC. (US) | 2020-08-06 | — | — | WO | disclosed |
| US-20070161608-A1 | Selective androgen receptor modulators for treating muscle wasting | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION | 2007-07-12 | — | — | US | disclosed |
| US-20070123563-A1 | Selective androgen receptor modulators and method of use thereof | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION | 2007-05-31 | — | — | US | disclosed |
| US-20070123563-A1 | Selective androgen receptor modulators and method of use thereof | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION | 2007-05-31 | — | — | US | disclosed |
| US-7205437-B2 | Selective androgen receptor modulators | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2007-04-17 | — | — | US | disclosed |
| US-7205437-B2 | Selective androgen receptor modulators | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2007-04-17 | — | — | US | disclosed |
| US-20070066568-A1 | Treating renal disease, burns, wounds and spinal cord injury with selective androgen receptor modulators | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION | 2007-03-22 | — | — | US | disclosed |
| WO-2007027582-A2 | TREATING RENAL DISEASE, BURNS, WOUNDS AND SPINAL CORD INJURY WITH SELECTIVE ANDROGEN RECEPTOR MODULATORS | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2007-03-08 | — | — | WO | disclosed |
| US-20050032750-A1 | Treating androgen deficiency in female (ADIF)-associated conditions with SARMS | GTX INC | 2005-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10987334-B2 | Method of treating ER mutant expressing breast cancers with selective androgen receptor modulators (SARMs) | AR, CDK6, PGR | AR 1/4885 |
| US-20230172897-A1 | METHODS OF TREATING BREAST CANCERS WITH SELECTIVE ANDROGEN RECEPTOR MODULATORS AND ADDITIONAL THERAPEUTIC AGENTS | AR, CYP19A1, NR5A1 | AR 1/4885 |
| US-20070066568-A1 | Treating renal disease, burns, wounds and spinal cord injury with selective androgen receptor modulators | AR, SARM1, OPRM1 | AR 1/4885 |
| US-20070123563-A1 | Selective androgen receptor modulators and method of use thereof | AR, SHBG, ESRRA | AR 1/4885 |
| US-20050032750-A1 | Treating androgen deficiency in female (ADIF)-associated conditions with SARMS | AR, SHBG, CYP19A1 | AR 1/4885 |
| US-20070161608-A1 | Selective androgen receptor modulators for treating muscle wasting | AR, ESRRA, SHBG | AR 1/4885 |
| US-20210228529-A1 | PHARMACEUTICAL COMPOSITIONS FOR TREATING BREAST CANCERS AND METHODS OF USES THEREOF | PGR, AR, CDK3 | AR 2/4885 |
| US-20210128513-A1 | NON-INVASIVE METHOD OF EVALUATING BREAST CANCERS FOR SELECTIVE ANDROGEN RECEPTOR MODULATOR (SARM) THERAPY | AR, CYP19A1, GNRHR | AR 1/4885 |
| US-10849873-B2 | Non-invasive method of evaluating breast cancers for selective androgen receptor modulator (SARM) therapy | AR, CYP19A1, GNRHR | AR 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.